Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CET
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
05:00p CVS HEALTH : Seekonk veteran joins Gillette Stadium camp
12/02 CVS HEALTH : To Host 2016 Analyst Day For The Investment Community
11/30 CVS HEALTH : Coverage change hurts patients
11/29 OPTUM : Rx and CVS Pharmacy Partner to Expand Consumer Choice, Reduce Costs and ..
11/25 CVS HEALTH : Patriots Football Skills Clinic for Veterans
11/22 BY THE NUMBERS : Consumer Perceptions About E-Cigarettes
11/22 CVS HEALTH : Pay goes live nationwide
11/21 CVS HEALTH : MinuteClinic Walk-in Medical Clinics Open in CVS Pharmacy Stores in..
11/19 CVS HEALTH : Cops report 2nd incident of a needle-wielding couple stealing drugs..
11/18 WASHINGTON TRUST BANCORP : Provides $2.5 Million in Financing for CVS Pharmacy i..
More news
Sector news : Drug Retailers - NEC
11/16DJWALGREENS BOOTS ALLIANCE : Claims Theranos Voided 11.3% of Test Reports
11/10 Trump victory clouds outlook for Time Warner-AT&T, other mergers
11/09 Trump stand on AT&T/Time Warner not indicative of M&A policy - analysts
11/09DJWALGREENS BOOTS ALLIANCE : Walgreen Sues Theranos, Seeking to Recover $140 Milli..
11/08DJWALGREENS BOOTS ALLIANCE : Seeks to Recover $140 Million Investment From Therano..
More sector news : Drug Retailers - NEC
News from SeekingAlpha
12/01 With 2016 Nearing A Close, Our Dividend Growth Portfolio Is Up Almost 10%
11/30 Three 10%+ Dividend Increases Among 11 Announcements Expected For December
11/27 The 'Coiled Spring' Of CVS
11/23 WALL STREET BREAKFAST : Traders Digest Fed Minutes Before Thanksgiving
11/23 Bloomberg reports aloe vera gel scam
Advertisement
Financials ($)
Sales 2016 178 016 M
EBIT 2016 10 716 M
Net income 2016 5 710 M
Debt 2016 24 219 M
Yield 2016 2,11%
P/E ratio 2016 15,53
P/E ratio 2017 14,14
EV / Sales 2016 0,60x
EV / Sales 2017 0,57x
Capitalization 82 777 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 88,0 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-21.36%82 777
WALGREENS BOOTS ALLIAN..-0.50%92 198
EXPRESS SCRIPTS HOLDIN..-13.44%46 654
MCKESSON CORPORATION-27.09%32 457
CARDINAL HEALTH INC-20.45%22 670
AMERISOURCEBERGEN CORP..-24.02%17 344
More Results